Fabrizio Stocchi

Fabrizio Stocchi

Auto-generated profile, based on publicly available information

Fabrizio Stocchi

Department of Neurology, University San Raffaele, Rome, Italy

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2009 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
PBPaolo Barone
Paolo Barone
Angelo AntoniniAngelo Antonini
Angelo Antonini
CCCarlo Colosimo
Carlo Colosimo
RMRoberto Marconi
Roberto Marconi
LMLetterio Morgante
Letterio Morgante
PDPaolo Del Dotto
Paolo Del Dotto

15 October 2007 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
PMPablo Martinez‐Martin
Pablo Martinez‐Martin
RBRichard G. Brown
Richard G. Brown
KSKapil Sethi
Kapil Sethi
FSFabrizio Stocchi
Fabrizio Stocchi
ASAnthony Schapira
Anthony Schapira

17 March 2006 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
PMPablo Martinez‐Martin
Pablo Martinez‐Martin
ASAnthony Schapira
Anthony Schapira
FSFabrizio Stocchi
Fabrizio Stocchi
KSKapil Sethi
Kapil Sethi
COCharles W. Olanow
Charles W. Olanow

24 September 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
COC. Warren Olanow
C. Warren Olanow
OROlivier Rascol
Olivier Rascol
RHRobert Hauser
Robert Hauser
PFPaul D. Feigin
Paul D. Feigin
JJJoseph Jankovic
Joseph Jankovic
ETEduardo Tolosa
Eduardo Tolosa
A therapy that slows disease progression is the major unmet need in Parkinson's disease. In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 mg or 2 mg per day) for 36 weeks (the delayed-start group). To determine a positive result with either dose, the early-start treatment group had to meet each of three hierarchical end points of the primary analysis based on the Unified Parkinson's Disease Rating Scale (UPDRS, a 176-point scale, with higher numbers indicating more severe disease): superiority to placebo in the rate of change in the UPDRS score between weeks 12 and 36, superiority to delayed-start treatment in the change in the score between baseline and week 72, and noninferiority to delayed-start treatment in the rate of change in the score between weeks 48 and 72. Early-start treatment with rasagiline at a dose of 1 mg per day met all end points in the primary analysis: a smaller mean (±SE) increase (rate of worsening) in the UPDRS score between weeks 12 and 36 (0.09±0.02 points per week in the early-start group vs. 0.14±0.01 points per week in the placebo group, P=0.01), less worsening in the score between baseline and week 72 (2.82±0.53 points in the early-start group vs. 4.52±0.56 points in the delayed-start group, P=0.02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0.085±0.02 points per week in the early-start group vs. 0.085±0.02 points per week in the delayed-start group, P<0.001). All three end points were not met with rasagiline at a dose of 2 mg per day, since the change in the UPDRS score between baseline and week 72 was not significantly different in the two groups (3.47±0.50 points in the early-start group and 3.11±0.50 points in the delayed-start group, P=0.60). Early treatment with rasagiline at a dose of 1 mg per day provided benefits that were consistent with a possible disease-modifying effect, but early treatment with rasagiline at a dose of 2 mg per day did not. Because the two doses were associated with different outcomes, the study results must be interpreted with caution. (ClinicalTrials.gov number, NCT00256204.)


1 August 2006 in The Lancet Neurology
Verified
Journal Article
Closed access
COC Warren Olanow
C Warren Olanow
JOJose A Obeso
Jose A Obeso
FSFabrizio Stocchi
Fabrizio Stocchi